Across TCGA pan-cancer cohorts, BTBD17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BTBD17 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BTBD17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BTBD17 expression acts as an unfavorable survival marker.

HNSC, SKCM, and LGG are the cancer types where BTBD17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.222	0.751	.007	12	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: BTBD17 tumor-vs-normal RNA expression · all BTBD17 data types